Vivos Therapeutics, Inc. (VVOS) News
Follow Vivos Therapeutics, Inc. (VVOS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Vivos Therapeutics Acquires Stake in SOD Sciences and 50% Test Interest
Vivos says the transaction is expected to add more than $10 million to stockholders' equity and open potential revenue opportunities through strategic alliances.
EQUITY | Oct 19, 2026, 09:07 PM UTC
M
Vivos Therapeutics to acquire SOD Sciences stake and test interest
Vivos Therapeutics agreed to acquire a minority stake in SOD Sciences and a 50% interest in its proprietary pseudohypoxia test.
EQUITY | Oct 15, 2026, 12:45 PM UTC
L
Vivos Therapeutics, Inc. (VVOS) Targets $3.6M Annual Cost Cuts, Eyes Cash-Flow Positive
Vivos Therapeutics announced a restructuring to cut about $3.6M annually starting Q4 2026 and outlined growth initiatives, including rising referrals, EEG testing run rate of $1.5—$3.0M in Q4, RPM up to $3.5M annualized
CENTRAL_BANK | Sep 29, 2026, 12:49 PM UTC
L
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line RevenueLITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.
EARNINGS | Sep 29, 2026, 12:49 PM UTC
L
VVOS debt reduction announced by Vivos Therapeutics
Vivos Therapeutics (VVOS) announced material debt reduction.
EQUITY | Sep 08, 2026, 12:45 PM UTC
M
Vivos Therapeutics swaps $2.86M Streeterville notes for up to 11.45M shares
Vivos Therapeutics entered twelve exchange agreements effective Aug 31, 2026 to convert $2,861,270 of partitioned Streeterville notes into up to 11,445,080 common shares at prices at or above Nasdaq minimums.
EQUITY | Sep 08, 2026, 10:04 AM UTC
L
Vivos Therapeutics to present at 2026 Moody Capital Solutions conference
Vivos Therapeutics, Inc. (VVOS) said it will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference.
EQUITY | Sep 01, 2026, 12:06 PM UTC
L
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASD
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
EQUITY | Aug 29, 2026, 01:22 PM UTC
L
VVOS to launch regional sleep testing and treatment center
Vivos Therapeutics and South Palm Cardiovascular Associates signed definitive agreements to launch a regional sleep testing and treatment center.
EQUITY | Aug 28, 2026, 12:47 PM UTC
L
Vivos Therapeutics (VVOS) reports record new patient referrals
Vivos Therapeutics reports record new patient referrals at its Nevada Sleep & Airway Medicine Centers, per TradeXchange Newsdesk, with no additional figures or catalyst provided.
EQUITY | Aug 25, 2026, 12:45 PM UTC
L
Vivos Therapeutics opens new sleep testing and treatment facility in Nevada
Vivos Therapeutics says it has opened a new sleep testing and treatment facility in Nevada to meet growing patient demand for sleep apnea testing and treatment.
EQUITY | Aug 20, 2026, 02:24 PM UTC
L
Vivos Therapeutics reports Q2 2026 financial results
Vivos Therapeutics (VVOS) reports second quarter 2026 financial results and provides an operational update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 08:28 PM UTC
L
Vivos Therapeutics schedules Q2 2026 results release
Vivos Therapeutics (VVOS) schedules the release of its second quarter 2026 financial results and a conference call, per the company’s announced timing.
EARNINGS | Aug 14, 2026, 12:45 PM UTC
M
Vivos Therapeutics Issues New US Patent
Vivos Therapeutics issues new US patent for oral device
EQUITY | Aug 05, 2026, 12:31 PM UTC
H
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Arista Networks Inc (NYSE: ANET ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued strong third-quarter guidance. Arista Networks re
EARNINGS | Aug 05, 2026, 08:57 AM UTC
L
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ: ALZN ) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ: VVOS ) shares increased by 9.92
GEOPOLITICS | Jun 30, 2026, 09:05 PM UTC
L
Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS ), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea
REGULATION | Jun 30, 2026, 12:47 PM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
M
VVOS Extends Financing Deal
Vivos Therapeutics extends Streeterville financing agreement through August 31, reaffirming plan to convert up to $4.5M debt into stock
EQUITY | Jun 22, 2026, 12:44 PM UTC
M
VVOS Extends Financing Deal
VVOS extends strategic financing deal through August 31, reaffirming plan to convert up to $4.5M debt into preferred and common stock
EQUITY | Jun 22, 2026, 12:40 PM UTC
L
VVOS Extends Financing Agreement
VVOS - Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
EQUITY | Jun 22, 2026, 12:31 PM UTC